Cormorant Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Cormorant Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-140,000	Closed	-$23.7M	–	57
2023 Q3	$23.7M	Buy	140,000 +60,000	+75%	+$11.3M	1.38%	19
2023 Q2	$17.3M	Hold	80,000	–	–	0.97%	26
2023 Q1	$14.5M	Sell	80,000 -30,000	-27%	-$5.74M	0.96%	30
2022 Q4	$21.6M	Sell	110,000 -40,000	-27%	-$8.58M	1.45%	25
2022 Q3	$33.7M	Buy	150,000 +25,000	+20%	+$5.06M	2.36%	13
2022 Q2	$15.8M	Sell	125,000 -25,000	-17%	-$2.87M	1.2%	26
2022 Q1	$19M	Buy	+150,000	New	+$16.9M	1.46%	20

Other funds holding KRTX

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Cormorant Asset Management's KRTX Position: Q4 2023 in Review

Cormorant Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023, closing a stake of 140,000 shares — an estimated $23.7M sold.

Cormorant Asset Management first reported a position in KRTX in Q1 2022 and held it in 7 quarters. The position peaked at $33.7M in Q3 2022. 328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

Cormorant Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Cormorant Asset Management sold 140,000 Karuna Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $23.7M.
Cormorant Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Cormorant Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $33.7M in Q3 2022.
328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Cormorant Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.